Olivier Spertini

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


91 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2012 | 2010 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1992 | 1991 | 1990 | 1986 | 1982 |
2024
 
Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.
Spertini C., Bénéchet A.P., Birch F., Bellotti A., Román-Trufero M., Arber C., Auner H.W., Mitchell R.A., Spertini O., Smirnova T., 2024/03/28. Cell death discovery, 10 (1) p. 157. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7BF16A506AF]
2023
 
Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.
Papadopoulou V., Schoumans J., Basset V., Solly F., Pasquier J., Blum S., Spertini O., 2023/12. Hematology, 28 (1) p. 2180704. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E1AEFA186EFE]
 
Comparative analysis of automated cell counts in oncological patients: Reliable results of point of care blood impedance measurements and pitfalls in myelodysplastic neoplasias and acute myeloid leukemias.
Blum S., Costanza M., Coutaz C., Naveiras O., Spertini O., Tsilimidos G., Alberio L., 2023/10. International journal of laboratory hematology, 45 (5) pp. 818-821. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BF3096D4C446]
MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology.
Sarkis R., Burri O., Royer-Chardon C., Schyrr F., Blum S., Costanza M., Cherix S., Piazzon N., Barcena C., Bisig B. et al., 2023/04. Modern pathology, 36 (4) p. 100088. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_352A9711DE44]
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.
Stalder G., Suffiotti M., Segot A., Noto A., Pantaleo G., Spertini O., Obeid M., 2023/01/01. Haematologica, 108 (1) pp. 234-239. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5551F9C73188]
2022
 
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen JJWM, Löwenberg B., Manz M., Biemond B.J., Westerweel P.E., Klein S.K., Fehr M., Sinnige HAM, Efthymiou A., Legdeur MCJC et al., 2022/09. Leukemia, 36 (9) pp. 2189-2195. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F6DB3CAE9A77]
 
High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.
Tschopp J., Brunel A.S., Spertini O., Croxatto A., Lamoth F., Bochud P.Y., 2022/08/25. Clinical infectious diseases, 75 (2) pp. 330-333. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D7EA460AD1EC]
 
Republication: Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.
Boller D., Doepfner K.T., Laurentiis A., Guerreiro A.S., Marinov M., Shalaby T., Depledge P., Robson A., Saghir N., Hayakawa M. et al., 2022/06. Anticancer research, 42 (6) pp. 3217-3230. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9296B74EEA42]
Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.
Ségot A., Stalder G., de Leval L., Solly F., Schoumans J., Basset V., Blum S., Spertini O., 2022/03/01. American journal of hematology, 97 (3) pp. E91-E93. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_92714D3B5868]
Isolated skin infiltration by a blastic plasmacytoid dendritic cell neoplasm.
Stalder G., Milowich D., Blum S., Schoumans J., Bisig B., Spertini O., 2022/02. EJHaem, 3 (1) pp. 259-260. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EC0E8BADE124]
2021
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.
Voruz S., Blum S., de Leval L., Schoumans J., Solly F., Spertini O., 2021/12/20. Biomarker research, 9 (1) p. 92. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3AC8AE13FD49]
CSF1R Inhibition Combined with GM-CSF Reprograms Macrophages and Disrupts Protumoral Interplays with AML Cells.
Smirnova T., Spertini C., Spertini O., 2021/10/21. Cancers, 13 (21) p. 5289. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BC60953C1C43]
 
Acute lymphoblastic leukaemia presenting as euglycaemic ketoacidosis in a patient with type 1 diabetes.
Gavillet M., Schaefer N., Lapointe A.K., Spertini O., Cairoli A., 2021/07. The Lancet. Haematology, 8 (7) pp. e534. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_26477222D566]
Invasive Hormographiella aspergillata infection in patients with acute myeloid leukemia: Report of two cases successfully treated and review of the literature.
Tschopp J., Perentes J.Y., Beigelman-Aubry C., Berezowska S., Lovis A., Spertini O., Bochud P.Y., Lamoth F., 2021/06. Medical mycology case reports, 32 pp. 68-72. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_723A4B6AD287]
 
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Löwenberg B., Pabst T., Maertens J., Gradowska P., Biemond B.J., Spertini O., Vellenga E., Griskevicius L., Tick L.W., Jongen-Lavrencic M. et al., 2021/02/23. Blood advances, 5 (4) pp. 1110-1121. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F33C1F2838B7]
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
Janssen J., Löwenberg B., Manz M., Bargetzi M., Biemond B., Borne PVD, Breems D., Brouwer R., Chalandon Y., Deeren D. et al., 2021/02/07. Cancers, 13 (4) p. 672. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E10B8DCDE22C]
 
Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia.
Martins F., Kruszewski M., Scarpelli I., Schoumans J., Spertini O., Lübbert M., Blum S., 2021/01. Annals of hematology, 100 (1) pp. 63-78. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_387FEDC64B22]
2020
 
Management of erroneous subcutaneous injection of vincristine.
de Goycoechea D., Dewarrat N., Rothuizen L.E., Matter M., Nagy M., Locher G., Spertini O., Blum S., 2020/10. Leukemia & lymphoma, 61 (10) pp. 2530-2532. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_641B75CE53D5]
 
Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm.
Blum S., Dunet V., Comoli P., Tirefort Y., Chalandon Y., Opota O., Comte D., Spertini O., Livio F., Brouland J.P. et al., 2020/09. Leukemia & lymphoma, 61 (9) pp. 2226-2229. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13EB95E6B61C]
Conidiobolus pachyzygosporus invasive pulmonary infection in a patient with acute myeloid leukemia: case report and review of the literature.
Stavropoulou E., Coste A.T., Beigelman-Aubry C., Letovanec I., Spertini O., Lovis A., Krueger T., Burger R., Bochud P.Y., Lamoth F., 2020/07/22. BMC infectious diseases, 20 (1) p. 527. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8DBE542AD411]
 
L’hématologie au temps du COVID-19 [Hematology in the time of COVID-19]
Gavillet M., Rufer N., Grandoni F., Carr Klappert J., Zermatten M.G., Cairoli A., Canellini G., Alberio L., Duchosal M.A., Spertini O. et al., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 823-826. Peer-reviewed.
[Pmid][serval:BIB_C2EE66B2AA4D]
Acute leukemia in the time of COVID-19.
Gavillet M., Carr Klappert J., Spertini O., Blum S., 2020/03/26. Leukemia research, 92 p. 106353. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_82B8BF1043A6]
 
Risk of B-cell lymphoma in MPN patients treated with JAK1/2 inhibitors: Contradictory results?
Costanza M., Spertini O., Blum S., 2020/03. Leukemia research, 90 p. 106313. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_10DE436CD9F2]
2019
 
The function of P-selectin glycoprotein ligand-1 is conserved from ancestral fishes to mammals.
Baïsse B., Spertini C., Galisson F., Smirnova T., Spertini O., 2019/12. Journal of leukocyte biology, 106 (6) pp. 1271-1283. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_747AB0288635]
 
Acute Myeloid and Lymphoblastic Leukemia Cell Interactions with Endothelial Selectins: Critical Role of PSGL-1, CD44 and CD43.
Spertini C., Baïsse B., Bellone M., Gikic M., Smirnova T., Spertini O., 2019/08/27. Cancers, 11 (9). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_98FCF1C4A7F6]
 
Ten-year single-centre experience in fertility preservation of 459 patients suffering from acute leukaemia.
Noetzli J., Voruz S., Wunder D., Primi M.P., Spertini O., Blum S., 2019/03. British journal of haematology, 184 (6) pp. 969-973. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9AD1D6CC6F77]
2018
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L., Thomas X., Bresler A.G., Raffoux E., Spertini O., Vey N., Marchand T., Récher C., Pigneux A., Girault S. et al., 2018/12. Haematologica, 103 (12) pp. 2033-2039. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A8F861CC78B6]
 
Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.
Brunel A.S., Wójtowicz A., Lamoth F., Spertini O., Neofytos D., Calandra T., Marchetti O., Bochud P.Y., 2018/11. Haematologica, 103 (11) pp. e527-e530. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_57E679722B16]
 
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Rahmé R., Ades L., Thomas X., Guerci-Bresler A., Pigneux A., Vey N., Raffoux E., Castaigne S., Spertini O., Wittnebel S. et al., 2018/11. Haematologica, 103 (11) pp. e519-e521. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9ECB1E4E3ADF]
 
Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.
Bloch J., Spertini O., Stucki A., Solly F., Blum S., 2018/10. Leukemia research, 73 pp. 103-104. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DA8C4FDC5E5F]
 
Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia.
Gavillet M., Spertini O., Blum S., 2018/07. Leukemia research, 70 pp. 87-90. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1FB6B3E560D]
 
Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013.
Schnegg-Kaufmann A., Feller A., Baldomero H., Rovo A., Manz M.G., Gregor M., Efthymiou A., Bargetzi M., Hess U., Spertini O. et al., 2018/02. Cancer epidemiology, 52 pp. 55-62. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2CECC2D87623]
2017
T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance.
Noetzli J., Gavillet M., Masouridi-Levrat S., Duchosal M., Spertini O., 2017/08. Clinical case reports, 5 (8) pp. 1320-1322. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F5940E9F0C9D]
 
Reversible granulocyte abnormalities after accidental ingestion of Colchicum autumnale.
Kritikos A., Spertini O., 2017/07/06. Blood, 130 (1) p. 95. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1BD5D7825A35]
 
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Löwenberg B., Pabst T., Maertens J., van Norden Y., Biemond B.J., Schouten H.C., Spertini O., Vellenga E., Graux C., Havelange V. et al., 2017/04/23. Blood, 129 (12) pp. 1636-1645. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_04ADFB38F5B5]
2015
 
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.
Braun T., Cereja S., Chevret S., Raffoux E., Beaumont M., Detourmignies L., Pigneux A., Thomas X., Bordessoule D., Guerci A. et al., 2015. Cancer, 121 (14) pp. 2393-2399. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BB0B5A543B4]
 
Progressive Organ Failure After Ingestion of Wild Garlic Juice
Galland-Decker C., Charmoy A., Jolliet P., Spertini O., Hugli O., Pantet O., 2015. Journal of Emergency Medicine, 50 (1) pp. 55-60. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8ED62DEA3ED3]
2012
Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine.
Gavillet M., Noetzli J., Blum S., Duchosal M.A., Spertini O., Lambert J.F., 2012/12. Haematologica, 97 (12) pp. 1929-1931. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B9132A398C21]
 
Ezrin-Radixin-Moesin-binding Sequence of PSGL-1 Glycoprotein Regulates Leukocyte Rolling on Selectins and Activation of Extracellular Signal-regulated Kinases.
Spertini C., Baïsse B., Spertini O., 2012. Journal of Biological Chemistry, 287 (13) pp. 10693-10702. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2E009BDCF43C]
 
Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.
Boller D., Doepfner K.T., DE Laurentiis A., Guerreiro A.S., Marinov M., Shalaby T., Depledge P., Robson A., Saghir N., Hayakawa M. et al., 2012. Anticancer Research, 32 (8) pp. 3015-3027.
[WoS][Pmid][serval:BIB_CD36CE57F3C8]
Using digital RNA counting and flow cytometry to compare mRNA with protein expression in acute leukemias.
Fernandez P., Solenthaler M., Spertini O., Quarroz S., Rovo A., Lovey P.Y., Leoncini L., Ruault-Jungblut S., D'Asaro M., Schaad O. et al., 2012. Plos One, 7 (11) pp. e49010. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FE015794D466]
2010
 
Chemotherapy is successful in sporadic late onset nemaline myopathy (SLONM) with monoclonal gammopathy.
Novy J., Rosselet A., Spertini O., Lobrinus J.A., Pabst T., Kuntzer T., 2010/02. Muscle & nerve, 41 (2) pp. 286-287. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_864F3EA6F2FD]
 
Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib.
Vedy Dana, Muehlematter Dominique, Rausch Thierry, Stalder Michele, Jotterand Martine, Spertini Olivier, 2010. Journal of Clinical Oncology, 28 (3) pp. e33-55.
[DOI][WoS][Pmid][serval:BIB_E51BF38E903E]
2008
 
P-selectin glycoprotein ligand-1 decameric repeats regulate selectin-dependent rolling under flow conditions.
Tauxe C., Xie X., Joffraud M., Martinez M., Schapira M., Spertini O., 2008. Journal of Biological Chemistry, 283 (42) pp. 28536-28545. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6803740F9A71]
 
Synthesis and Biological Evaluation of S-Neofucopeptides as E- and P-Selectin Inhibitors.
Moreno-Vargas A.J., Molina L., Carmona A.T., Ferrali A., Lambelet M., Spertini O., Robina I., 2008. European Journal of Organic Chemistry 17 pp. 2973-2982. Peer-reviewed.
[DOI][WoS][serval:BIB_5F1C21053F1F]
2007
Evolutionary conservation of P-selectin glycoprotein ligand-1 primary structure and function.
Baïsse B., Galisson F., Giraud S., Schapira M., Spertini O., 2007/09/14. BMC evolutionary biology, 7 p. 166. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1350E79FFA3E]
 
Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway
Doepfner K. T., Spertini O., Arcaro A., 2007/09. Leukemia, 21 (9) pp. 1921-1930.
[DOI][WoS][Pmid][serval:BIB_06F5E81378B2]
 
Management of an acute coronary syndrome in a patient with severe haemophilia A.
Ferrario C., Renders F., Cairoli A., Vuffray A., Spertini O., Angelillo-Scherrer A., 2007. Haemophilia, 13 (6) pp. 763-765. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1798227017B0]
2006
 
Lipid raft adhesion receptors and Syk regulate selectin-dependent rolling under flow conditions
Abbal C., Lambelet M., Bertaggia D., Gerbex C., Martinez M., Arcaro A., Schapira M., Spertini O., 2006/11. Blood, 108 (10) pp. 3352-3359.
[DOI][WoS][Pmid][serval:BIB_1BE23A3E9556]
 
Dermatomyositis, lobar panniculitis and inflammatory myopathy with abundant macrophages
Carrera E., Lobrinus J. A., Spertini O., Gherardi R. K., Kuntzer T., 2006/07. Neuromuscular Disorders, 16 (7) pp. 468-471. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3CFAA62FAAC0]
Images in clinical medicine. Spurious platelet count
Siegenthaler M., Spertini O., 2006/05. New England Journal of Medicine, 354 (18) p. 1936.
[URN][DOI][WoS][Pmid][serval:BIB_E18D7B8B3DBB]
2005
 
Eosinophilic perimyositis as the presenting feature of a monoclonal T-cell expansion
Dunand M., Lobrinus J. A., Spertini O., Kuntzer T., 2005/05. Muscle and Nerve, 31 (5) pp. 646-651. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_024D14F28AC3]
 
Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII.
Martinez M., Joffraud M., Giraud S., Baïsse B., Bernimoulin M.P., Schapira M., Spertini O., 2005. Journal of Biological Chemistry, 280 (7) pp. 5378-5390. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7F00885DFDE]
2004
 
A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation.
Hauert J., Fernandez-Carneado J., Michielin O., Mathieu S., Grell D., Schapira M., Spertini O., Mutter M., Tuchscherer G., Kovacsovics T., 2004. Chembiochem, 5 (6) pp. 856-864. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_87B27414B1B6]
 
New nonhydrolyzable mimetics of sialyl Lewis X and their binding affinity to P-selectin
Carrel F., Giraud S., Spertini O., Vogel P., 2004. Helvetica Chimica Acta, 87 pp. 1048-1070.
[WoS][serval:BIB_7FE3FB7A9A2B]
2003
 
NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC
Silva A. P., Cavadas C., Baisse-Agushi B., Spertini O., Brunner H. R., Grouzmann E., 2003/11. Regulatory Peptides, 116 (1-3) pp. 71-79.
[DOI][WoS][Pmid][serval:BIB_7AE041F76593]
 
Molecular basis of leukocyte rolling on PSGL-1. Predominant role of core-2 O-glycans and of tyrosine sulfate residue 51.
Bernimoulin M.P., Zeng X.L., Abbal C., Giraud S., Martinez M., Michielin O., Schapira M., Spertini O., 2003. The Journal of biological chemistry, 278 (1) pp. 37-47. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AA4E1EBF172B]
2001
 
Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination
Stucki A., Rivier A. S., Gikic M., Monai N., Schapira M., Spertini O., 2001/04. Blood, 97 (7) pp. 2121-2129.
[DOI][WoS][Pmid][serval:BIB_6515DA3D13EF]
2000
 
Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate.
Xie X., Rivier A.S., Zakrzewicz A., Bernimoulin M., Zeng X.L., Wessel H.P., Schapira M., Spertini O., 2000/11. Journal of Biological Chemistry, 275 (44) pp. 34818-34825. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0596CF80F236]
 
Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin
Andre P., Spertini O., Guia S., Rihet P., Dignat-George F., Brailly H., Sampol J., Anderson P. J., Vivier E., 2000/03. Proceedings of the National Academy of Sciences of the United States of America, 97 (7) pp. 3400-3405.
[DOI][WoS][Pmid][serval:BIB_6D78364F7613]
1999
 
Elastase and metalloproteinase activities regulate soluble complement receptor 1 release
Sadallah S., Hess C., Miot S., Spertini O., Lutz H., Schifferli J. A., 1999/11. European Journal of Immunology, 29 (11) pp. 3754-3761.
[WoS][Pmid][serval:BIB_7F3C867260AB]
 
Soluble complement receptor 1 is increased in patients with leukemia and after administration of granulocyte colony-stimulating factor
Sadallah S., Lach E., Schwarz S., Gratwohl A., Spertini O., Schifferli J. A., 1999/01. Journal of Leukocyte Biology, 65 (1) pp. 94-101.
[WoS][Pmid][serval:BIB_B86806165A17]
1998
 
Relationship between cleaved L-selectin levels and the outcome of acute myeloid leukemia
Extermann M., Bacchi M., Monai N., Fopp M., Fey M., Tichelli A., Schapira M., Spertini O., 1998/11. Blood, 92 (9) pp. 3115-3122.
[WoS][Pmid][serval:BIB_4C3DAAF28FC5]
 
Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology
Yilmaz A., Bieler G., Spertini O., Lejeune F. J., Ruegg C., 1998/08. International Journal of Cancer, 77 (4) pp. 592-599.
[WoS][Pmid][serval:BIB_6196BC609FB9]
 
The Fcgamma receptor-mediated respiratory burst of rolling neutrophils to cytokine-activated, immune complex-bearing endothelial cells depends on L-selectin but not on E-selectin
Frohlich D., Spertini O., Moser R., 1998/04. Blood, 91 (7) pp. 2558-2564.
[WoS][Pmid][serval:BIB_368C0954C090]
1997
Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans
Giuffre L., Cordey A. S., Monai N., Tardy Y., Schapira M., Spertini O., 1997/02. Journal of Cell Biology, 136 (4) pp. 945-956.
[URN][DOI][WoS][Pmid][serval:BIB_6924C9E33A88]
 
Plasminogen activators play an essential role in extracellular-matrix invasion by lymphoblastic T cells
Reiter L. S., Spertini O., Kruithof E. K., 1997/02. International Journal of Cancer, 70 (4) pp. 461-466.
[DOI][WoS][Pmid][serval:BIB_DCEA1CAB4A94]
 
Circulating adhesion receptor in Health and Disease
Spertini O., 1997. 123-154.
[serval:BIB_3D75259D8032]
1996
 
Regulation de la migration leucocytaire par les molecules d'adhesion. [Regulation of leukocyte migration by adhesion molecules]
Spertini O., 1996/11. Schweizerische Medizinische Wochenschrift, 126 (45) pp. 1926-1934.
[WoS][Pmid][serval:BIB_F6DE6C1DF830]
P-selectin glycoprotein ligand 1 is a ligand for L-selectin on neutrophils, monocytes, and CD34+ hematopoietic progenitor cells
Spertini O., Cordey A. S., Monai N., Giuffre L., Schapira M., 1996/10. Journal of Cell Biology, 135 (2) pp. 523-531.
[URN][DOI][WoS][Pmid][serval:BIB_23A7D5F56FB1]
1995
 
Cleaved L-selectin concentrations in meningeal leukaemia
Stucki A., Cordey A. S., Monai N., de Flaugergues J. C., Schapira M., Spertini O., 1995/02. Lancet, 345 (8945) pp. 286-289.
[DOI][WoS][Pmid][serval:BIB_AACF30B61013]
1994
 
High levels of the shed form of L-selectin are present in patients with acute leukemia and inhibit blast cell adhesion to activated endothelium
Spertini O., Callegari P., Cordey A. S., Hauert J., Joggi J., von Fliedner V., Schapira M., 1994/08. Blood, 84 (4) pp. 1249-1256.
[WoS][Pmid][serval:BIB_938B44B4CB03]
1992
 
ELISA for quantitation of L-selectin shed from leukocytes in vivo
Spertini O., Schleiffenbaum B., White-Owen C., Ruiz, P., Jr. , Tedder T. F., 1992/11. Journal of Immunological Methods, 156 (1) pp. 115-123.
[DOI][WoS][Pmid][serval:BIB_2EA8F3BC93B2]
 
Neutrophils, monocytes, and lymphocytes bind to cytokine-activated kidney glomerular endothelial cells through L-selectin (LAM-1) in vitro
Brady H. R., Spertini O., Jimenez W., Brenner B. M., Marsden P. A., Tedder T. F., 1992/10. Journal of Immunology, 149 (7) pp. 2437-2444.
[WoS][Pmid][serval:BIB_1440551FA015]
Soluble L-selectin is present in human plasma at high levels and retains functional activity
Schleiffenbaum B., Spertini O., Tedder T. F., 1992/10. Journal of Cell Biology, 119 (1) pp. 229-238.
[URN][DOI][WoS][Pmid][serval:BIB_D528B73921E0]
 
Monocyte attachment to activated human vascular endothelium in vitro is mediated by leukocyte adhesion molecule-1 (L-selectin) under nonstatic conditions
Spertini O., Luscinskas F. W., Gimbrone, M. A., Jr. , Tedder T. F., 1992/06. Journal of Experimental Medicine, 175 (6) pp. 1789-1792.
[DOI][WoS][Pmid][serval:BIB_6DF473692FA3]
 
Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells
Mackay C. R., Marston W. L., Dudler L., Spertini O., Tedder T. F., Hein W. R., 1992/04. European Journal of Immunology, 22 (4) pp. 887-895.
[DOI][WoS][Pmid][serval:BIB_CD53336B55B4]
 
Reaction of acetaldehyde with human platelets
Spertini O., Hauert J., Bachmann F., 1992/01. Thrombosis and Haemostasis, 67 (1) pp. 126-130.
[WoS][Pmid][serval:BIB_751F7D78DA1D]
1991
 
An activated CD8+ lymphocyte appears in lymph nodes of rhesus monkeys early after infection with simian immunodeficiency virus
Reimann K. A., Snyder G. B., Chalifoux L. V., Waite B. C., Miller M. D., Yamamoto H., Spertini O., Letvin N. L., 1991/10. Journal of Clinical Investigation, 88 (4) pp. 1113-1120.
[DOI][WoS][Pmid][serval:BIB_813FF2C55C8C]
 
Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion
Spertini O., Luscinskas F. W., Kansas G. S., Munro J. M., Griffin J. D., Gimbrone, M. A., Jr. , Tedder T. F., 1991/10. Journal of Immunology, 147 (8) pp. 2565-2573.
[WoS][Pmid][serval:BIB_89310E17573D]
 
Function and evolutionary conservation of distinct epitopes on the leukocyte adhesion molecule-1 (TQ-1, Leu-8) that regulate leukocyte migration
Spertini O., Kansas G. S., Reimann K. A., Mackay C. R., Tedder T. F., 1991/08. Journal of Immunology, 147 (3) pp. 942-949.
[WoS][Pmid][serval:BIB_747C3E392674]
Molecular mapping of functional domains of the leukocyte receptor for endothelium, LAM-1
Kansas G. S., Spertini O., Stoolman L. M., Tedder T. F., 1991/07. Journal of Cell Biology, 114 (2) pp. 351-358.
[URN][DOI][WoS][Pmid][serval:BIB_49AFE3D20FDD]
 
Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells
Spertini O., Freedman A. S., Belvin M. P., Penta A. C., Griffin J. D., Tedder T. F., 1991/04. Leukemia, 5 (4) pp. 300-308.
[WoS][Pmid][serval:BIB_03043A3984BA]
 
Dysmegakaryopoiesis predicting response to therapy in acute myeloid leukaemia. A histologic and clinical study
Delacretaz F., Spertini O., Schmidt P.M., Grob J.P., 1991/03. Pathology, Research and Practice, 187 (2-3) pp. 290-295.
[WoS][Pmid][serval:BIB_FFDA4E86CFCC]
 
Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin
Spertini O., Kansas G. S., Munro J. M., Griffin J. D., Tedder T. F., 1991/02. Nature, 349 (6311) pp. 691-694.
[DOI][WoS][Pmid][serval:BIB_A971D4751854]
1990
 
Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors
Griffin J. D., Spertini O., Ernst T. J., Belvin M. P., Levine H. B., Kanakura Y., Tedder T. F., 1990/07. Journal of Immunology, 145 (2) pp. 576-584.
[WoS][Pmid][serval:BIB_9EC5F2D2DA92]
 
Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils.
Ord D.C., Ernst T.J., Zhou L.J., Rambaldi A., Spertini O., Griffin J., Tedder T.F., 1990/05. Journal of Biological Chemistry, 265 (14) pp. 7760-7767. Peer-reviewed.
[WoS][Pmid][serval:BIB_5F745C3DE0F8]
1986
 
Immune response to purified non-A, non-B hepatitis-related antigen demonstrated by leukocyte migration inhibition in patients recovering from the infection
Nicole A., Spertini O., Lavanchy D., Frei P. C., 1986/02. Infection, 14 (1) pp. 13-16.
[DOI][WoS][Pmid][serval:BIB_878F67C96F60]
 
Biophysical properties and morphology of purified antigen associated with non-A, non-B hepatitis.
Spertini O., Frei P.C., 1986. Medical Microbiology and Immunology, 175 (4) pp. 229-239. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_964BA962A3B9]
1982
 
Demonstration of a single antigen-antibody system in 26 patients with non-A, non-B viral hepatitis
Spertini O., Frei P. C., 1982/10. Lancet, 2 (8304) pp. 899-900.
[WoS][Pmid][serval:BIB_E8B136EC1245]
 
Les hepatites virales: tableaux cliniques, marqueurs immunologiques et vaccination. [Viral hepatitis: clinical aspects, immunologic markers and vaccination]
Frei P. C., Nicole A., Spertini O., 1982/09. Therapeutische Umschau, 39 (9) pp. 692-699.
[WoS][Pmid][serval:BIB_0F2F6CB39856]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University